Introduction
Deafferentation pain is defined as pain that occurs in an area of diminished or abnormal sensation.' The anatomical site of origin of such pain can be either peripheral, such as in post-herpetic neuralgia, or central, as observed in patients with pain due to thalamic syndrome following a stroke. The mechanism of deafferentation pain is poorly understood and the patients usually do not derive benefits from narcotic or non-narcotic analgesics.2 Tricyclic antidepressants and anticonvulsants are often prescribed in this condition for pain originating both peripherally and centrally, sometimes with limited benefit. Transcutaneous nerve stimulation or nerve block may relieve pain in patients with pain originating peripherally,3 but such therapy is usually available in a specialized pain clinic. The opioid antagonist, naloxone, has been reported to be effective in alleviating thalamic pain. 4 This drug is known to have adverse effects on the cardiovascular system, such as cardiac arrhythmia,5 and is therefore potentially hazardous for the elderly patients. Although a recent study indicates that naloxone is probably safe to use if the dose is increased step by step over several weeks,4 this drug needs to be administered intravenously.
I report here on the beneficial effect of pizotifen,6 a 5-hydroxytryptamine (5-HT) antagonist, in 4 elderly patients with deafferentation pain.
Case reports
Case I An 83 year old female patient with previous history of transient ischaemic attacks was admitted following an acute stroke and left flaccid hemiplegia. She made no significant neurological progress and was eventually transferred to a continuing care ward. Four to five weeks after her stroke, she developed persistent burning excruciating pain over the hemiplegic upper limb, left side of the neck and face, associated with hyperaesthesia and occasional involuntary movements of left arm. Her pain was worse following touch or slight change ofposture, for example, during routine nursing care. Conventional analgesics (such as morphine, non-steroidal anti-inflammatory drugs, local analgesic spray, tranquillizers and antidepressants) failed to produce any relief. She developed visual hallucinations and became confused following 2 weeks' treatment with 75 mg imipramine daily.
It was decided to try pizotifen which was initially prescribed at a dose of 1.5 mg as a bedtime medication. Within one week's treatment, she was reported to be sleeping better at nights and shouting less from pain during washing/dressing in the mornings. In view of her previous intolerance to imipramine, after 2 months' treatment, the dose of pizotifen was cautiously increased to 1.5 mg twice daily, with further improvement of her symptoms. Intensity of her pain appeared to be increased after 4 months' medication. The dose was increased to 1.5 mg thrice daily, again with symptomatic improvement.
Although she never became completely free from pain, with this regime she was able to tolerate physiotherapy and the usual nursing procedures better than before. She also appeared to be more cheerful and sociable. No obvious side effects were observed.
Her condition remained stable when this regime was continued for another 2.5 months, but after that the intensity of pain again increased. As pizotifen is not a recognized therapy for thalamic syndrome, her analgesic drug regime was altered without much success by another clinician, after this author's departure from that hospital. She had no significant relief of pain from various analgesics and developed maculopapular rash following pentazocine. At the time of referral she was taking a cocktail of amitriptyline, meptazinol and chlorpheniramine, in addition to temazepam at night. These drugs made her extremely dizzy and she was unable to stand or walk, and became almost housebound. She was depressed and had no confidence even to attend an out-patient clinic. Prior to the onset of her illness she was independent in all aspects. Her current medication was stopped and her general practitioner was advised to prescribe carbamazepine starting from a dose of 100mg/day, increasing to 400-600mg/day, according to her tolerance and response. Although carbamazepine (600mg/day) partially controlled her pain, she remained dizzy. The dose was therefore reduced to 300mg/day, which was inadequate to control her pain. Combination of amitriptyline and carbamazepine were without any benefit and increased the side effects. Since carbamazepine at higher dose level produced some symptomatic improvement, it was therefore decided to add pizotifen 1.5 mg thrice daily to 300 mg of carbamazepine. She improved within a week and became asymptomatic within 4 weeks. She was followed up at the clinic. Carbamazepine was discontinued after 3 months and pizotifen after another 7 months' therapy. She remained well without any recurrence.
Discussion
Pizotifen is not a conventional analgesic and is usually recommended for patients with migraine. It was therefore prescribed as a last resort to these four patients who derived no benefit from conventional narcotic and non-narcotic drugs. Two Whatever may be the mode of action, it is interesting to note that the two patients with thalamic syndrome showed some evidence of increasing tolerance to pizotifen's analgesic effect. Since neither the plasma drug level nor any other pharmacological effect, such as its antagonizing effect on the platelet 5-HT uptake activity" was monitored, it is difficult to comment whether this was a pharmacokinetic or pharmacodynamic tolerance. Similar tolerance has recently been reported in patients with thalamic syndrome using intravenous naloxone therapy.4
Thalamic syndrome is a relatively uncommon complication of stroke and it is therefore difficult to conduct a controlled clinical trial involving patients from only one centre. In a recent report on the effect of naloxone in this condition, the authors quoted only 4 patients.4 Obviously, further controlled clinical studies are required to verify pizotifen's beneficial effect in deafferentation pain, a condition for which no oral therapy with proven benefit at present exists.
